Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
To the editor: We read with interest the recent paper by Polasek et al. on the evaluation of zolpidem as a mechanism-based inactivator of human CYP3A in vitro that was accompanied by the assessment of its metabolic interaction potential with CYP3A drugs [1]. The article clearly points out the mechanism of inactivation of human CYP3A in vitro and describes the implications of this mechanism for the in vivo metabolic interactions involving CYP3A. Given the prescription rate of zolpidem, this issue is of vital importance in terms of the drug’s efficacy and patients’ safety. However, one issue that was not addressed in the discussion of this interesting paper is that of the association between the patient’s sex and the endocrine specificity of zolpidem—as if zolpidem pharmacokinetics is a gender-independent factor. Based on current knowledge, the pharmacokinetics of zolpidem seems to be related to endocrine factors associated with CYP3A4 metabolism. As such, low plasma concentrations of free testosterone may contribute to lower CYP3A activity, with women achieving up to 50% higher zolpidem plasma levels, while exposure to testosterone activates the biotransformation via CYP3A [2]. This effect is conspicuous in the relative higher incidence of adverse drug reactions with zolpidem in women [3]. The conclusions of the study reported in the paper are valid for the model study on male subjects. It would have been interesting, however, if the discussion were to have included the exciting element of endocrine-related differences in zolpidem action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01852.x · Cited by 104
Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects
Cubała, W. J., Landowski, J., & Wichowicz, H. M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03028.x · Cited by 34
Self-citation
Cited by
Exploring Sex and Gender Differences in Sleep Health: A Society for Women's Health Research Report
Mallampalli, M. P., & Carter, C. L. (2014) · Journal of Women's Health · doi:10.1089/jwh.2014.4816 · Cited by 504
“As discussed above, zolpidem is the only hypnotic that has shown gender-specific changes in metabolism.(23,70)”
Rich-Edwards, J. W., Kaiser, U. B., Chen, G. L., Manson, J. E., & Goldstein, J. M. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00246 · Cited by 273
Associations between sex hormones, sleep problems and depression: A systematic review
Morssinkhof, M. W. L., van Wylick, D. W., Priester-Vink, S., van der Werf, Y. D., den Heijer, M., van den Heuvel, O. A., & Broekman, B. F. P. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.08.006 · Cited by 257
“The American Food and Drug Administration (FDA) renewed its guideline for the benzodiazepine Zolpidem to a 50% lower dose in women because it metabolizes more slowly in women, the first ever sex-specific guideline for benzodiazepines (Cubała et al., 2010; Food and Drug Administration, 2018).”
Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review
Ho, T., Jimenez, A., Sanchez, I., Seeger, C., & Joseph, M. (2020) · Sleep Medicine: X · doi:10.1016/j.sleepx.2020.100019 · Cited by 17
Metadata
- Authors
- Cubała, W. J., Wiglusz, M., Burkiewicz, A., & Gałuszko-Węgielnik, M.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2010-06-16
- Volume
- 66
- Issue
- 9
- Pages
- 955-955
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2094249405
- Cited by
- 27
- References
- 2
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. https://app.cochat.ai/papers/10.1007/s00228-010-0854-x
- The paper
- Cubała, W. J., Wiglusz, M., Burkiewicz, A., & Gałuszko-Węgielnik, M. (2010). Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-010-0854-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.